GeneLink Receives International Patent for Age-Associated Oxidative Stress Test
July 14, 2005

JERSEY CITY, NJ – (Business Wire) – December 27th, 2005– GeneLink BioSciences, Inc. (OTCBB: GNLK) announced today that the Australian Patent Office issued GeneLink a patent for its oxidative stress test. Australian Patent number 2002309543, entitled "KITS AND METHODS FOR ASSESSING OXIDATIVE STRESS." was granted on October 6, 2005. This is the second patent to be granted from a family of applications filed by GeneLink in the U.S. and abroad.

GeneLink’s proprietary DNA test for oxidative stress is used to genetically predict an individual’s risk for a variety of age-associated conditions. Oxidative Stress occurs when there is an accumulation of destructive molecules called free radicals that damage the integrity of the cells by destroying proteins and DNA. The oxidative stress theory suggests that degenerative diseases associated with aging may be attributed to the effects of these free radicals on the body’s cells.

PENDING PATENTS: “GeneLink believes that grant of this Australian patent further confirms GeneLink's confidence in the commercial potential of its technology,” says Monte Taylor, Jr., GeneLink’s acting CEO. “In addition to the Oxidative Stress Test, GeneLink has expanded its genetic test offerings to include: Dermagenetics® (Skin Health) Panel, Comprehensive Cardio Panel, Lipid Metabolism Panel, Bone Density Panel and CoQ10 Efficiency.”

Based on the analysis of key genes, GeneLink’s genetic tests provide information that enables customization of nutritional and skin-care products, as well as development of health maintenance care regimens personalized to meet the individual consumer’s need.

GeneLink offers genetic tests to companies that distribute to the $100 Billion plus health care, nutritional supplement and skin-care industries. Through Its subsidiary, DERMAGENETICSÒ, markets its DNA UltraCustom system of “genetically guided” skin-care products to the spa and medi-spa industries.

For more information visit www.genelink.info; for more information about the Dermagenetics system, visit www.dermagenetics.com

This release contains certain forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in the press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement. GNLK disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future developments or otherwise.